StemCell Therapy

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results/Quarterly / Interim StatementB.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

31.08.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

Zwingenberg, Germany31 August 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first nine months of the 2019/20 financial year. Accordingly, the BRAIN Group reports revenues of ? 29.6 million compared to ? 27.9 million in the same period of the previous year. Taking into account the deconsolidation of Monteil Cosmetics GmbH, this corresponds to organic growth of 12.2%.

Third quarter revenues increased by 8.4% to ? 9.6 million from ? 8.9 million in the same period last year. This growth was purely organic, achieved in both the BioScience and BioIndustrial segments.

"Particularly considering the general economic situation, we have achieved very good growth," says Manfred Bender, CFO of BRAIN AG. "The fact that this growth is more pronounced in our research-driven segment is again due to the higher business volume with existing customers as well as new contracts for tailormade solutions projects."

Development by segments

The BioScience segment generated revenues of ? 10.5 million in the reporting period, up 37.5% from the prior-year period. Adjusted EBITDA improved from ? -4.4 million to ? -3.1 million.

Revenues of the BioIndustrial segment, which is related to product sales, decreased by 5.9% from ? 20.3 million to ? 19.1 million in the reporting period. Organically, revenues here increased by ? 0.4 million or 2.1% from ? 18.7 million to ? 19.1 million. The adjusted EBITDA of the segment developed positively and increased by 9.2% from ? 2.3 million to ? 2.6 million. This corresponds to an adjusted EBITDA margin of 13.3% compared to 11.5% in the previous year.

The reasons for the weaker revenue growth in the product business are, in addition to the start of new production facilities in Cardiff (UK) and Bttelborn, the globally reduced demand for bioethanol and alcoholic beverages due to the Corona pandemic. The BRAIN subsidiary WeissBioTech supplies, among others, powerful enzymes to bioethanol producers and the wine industry.

Despite the ongoing Corona virus pandemic and the associated economic uncertainty, BRAIN AG is still confident to make further progress in the projected direction, albeit possibly at a slightly slower pace.

Key financials (first nine months of fiscal year 2019/20)

More detailed information on the financial results are available at http://www.brain-biotech.com/investors/financial-publications as part of the quarterly statement for the period ended 30 June 2020.

Financial Calendar:

http://www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners ("Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-6251-9331-86Email: mis@brain-biotech.com

Contact MediaDr. Stephanie KonlePhone: +49-(0)-6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continue reading here:
BRAIN Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year -...

The 39 rating InvestorsObserver gives to Menlo Therapeutics Inc (MNLO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 29 percent of stocks in the Biotechnology industry, MNLOs 39 overall rating means the stock scores better than 39 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Menlo Therapeutics Inc (MNLO) stock has risen 4.73% while the S&P 500 is lower by -0.03% as of 3:12 PM on Monday, Aug 31. MNLO is up $0.07 from the previous closing price of $1.48 on volume of 1,790,999 shares. Over the past year the S&P 500 has gained 20.67% while MNLO is lower by -67.98%. MNLO lost -$3.75 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Read more from the original source:
Is Menlo Therapeutics Inc (MNLO) a Winner in the Biotechnology Industry? - InvestorsObserver

Iovance Biotherapeutics Inc (IOVA) is near the middle in its industry group according to InvestorsObserver. IOVA gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Iovance Biotherapeutics Inc gets a 53 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock is higher by 4.39% while the S&P 500 has fallen -0.08% as of 11:20 AM on Monday, Aug 31. IOVA has risen $1.39 from the previous closing price of $31.68 on volume of 584,032 shares. Over the past year the S&P 500 is up 20.60% while IOVA has risen 63.15%. IOVA lost -$1.93 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.

More:
Is Iovance Biotherapeutics Inc (IOVA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 63 rating InvestorsObserver gives to Heat Biologics Inc (HTBX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, HTBXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heat Biologics Inc (HTBX) stock is trading at $1.26 as of 9:52 AM on Monday, Aug 31, a decline of -$0.08, or -5.97% from the previous closing price of $1.34. The stock has traded between $1.25 and $1.36 so far today. Volume today is below average. So far 1,467,087 shares have traded compared to average volume of 35,406,604 shares.

To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.

Read the original here:
Is Heat Biologics Inc (HTBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

TheGlobal Agricultural Biotechnology Market To Gain Massive Profits During Projected TimespanA fundamental outline of theAgricultural Biotechnology Marketniche is presented by the Agricultural Biotechnology Market report that entails definitions, classifications, applications together with industry chain framework. TheAgricultural Biotechnology Marketreport provides a far-reaching evaluation of necessary market dynamics and the latest trends. It also highlights the regional market, the prominent market players, as well as several market segments [Product, Applications, End-Users, and Major Regions], and sub-segments with a wide-ranging consideration of numerous divisions with their applications.

Request Free Sample Report of Agricultural Biotechnology Market Report @https://www.zionmarketresearch.com/sample/agricultural-biotechnology-market

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Some of the Major Market Players Are:

Monsanto, Vilmorin, Bayer CropScience, Syngenta, Certis, DuPont Pioneer Hi-Bred, Evogene, KWS SAAT, Dow AgroSciences

Further, the report acknowledges that in these growing and promptly enhancing market circumstances, the most recent advertising and marketing details are very important to determine the performance in the forecast period and make essential choices for profitability and growth of the Agricultural Biotechnology Market. In addition, the report encompasses an array of factors that impact the growth of the Agricultural Biotechnology Market in the forecast period. Further, this specific analysis also determines the impact on the individual segments of the market.

Furthermore, the study assessed major market elements, covering the cost, capacity utilization rate, growth rate, capacity, production, gross, usage, revenue, export, supply, price, market share, gross margin, import, and demand. In addition, the study offers a thorough segmentation of the global Agricultural Biotechnology Market on the basis of geography [ Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] , technology, end-users, applications, and region.

Download Free PDF Report Brochure@https://www.zionmarketresearch.com/requestbrochure/agricultural-biotechnology-market

The Agricultural Biotechnology Market report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.

The Agricultural Biotechnology Market report is an appropriate compilation of all necessary data for the residential, industrial. & commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projected as well as the prevailing trends in the Agricultural Biotechnology Market. Apart from this, the report also provides insightful particulars of the existing policies, laws, together with guidelines.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/agricultural-biotechnology-market

Promising Regions & Countries Mentioned In The Agricultural Biotechnology Market Report:

Chapters Covered in Research Report are :

Chapter 1,2 :The goal of global Agricultural Biotechnology Market covering the market introduction, product image, market summary and development scope.

Chapter 3, 4 :Global Market Competitions by Manufacturers, Sales Volume and Market Profit.

Chapter 5,6,7:Global Supply (Production), Consumption, Export, Import by Regions like United States, Asia-Pacific, China, India, Japan. Conducts the region-wise study of the market based on the sales ratio in each region, and market share from 2015 to 2024

Chapter 8,9,10:Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributors/Traders

Chapter 11,12 :Market information and study conclusions, appendix and data sources.

The market report also identifies further useful and usable information about the industry mainly includes Agricultural Biotechnology Market development trend analysis, investment return and feasibility analysis. Further, SWOT analysis is deployed in the report to analyze the key global market players growth in the Agricultural Biotechnology Market industry

Purposes Behind Buying Agricultural Biotechnology Market Report:-

Key questions answered in this comprehensive study Global Agricultural Biotechnology Market Size, Status and Forecast 2026

Request the coronavirus impact analysis across industries and market

Request impact analysis on this markethttps://www.zionmarketresearch.com/custom/8?covid19=true

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

View original post here:
Global Agricultural Biotechnology Market To Gain Massive Profits During Projected Timespan - Galus Australis

BEDFORD, N.H., Aug. 27, 2020 /PRNewswire/ --LSNE Contract Manufacturing, a leading contract development and manufacturing organization, is pleased to announce that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical stage biotechnology based therapeutic products at its aseptic fill finish facility in Len, Spain. This important approval builds upon LSNE's well-established capabilities in providing aseptic fill finish of biologic products for clients at its US facilities. These products include monoclonal antibodies, fusion proteins, replacement enzymes, plasmids, capsids, and oligonucleotides.

"The authorization of biologic manufacturing for clinical drug product in both vial and pre-filled syringe (PFS) presentations is a vital step to our maturation of drug product manufacturing at our facility in Spain. This will provide the global market with more access to LSNE facilities for the manufacture of these high-value biologics, including monoclonal antibodies and other recombinant proteins," said Shawn Cain, LSNE's Chief Operating Officer.

Jaime Del Campo, Site Head at LSNE-Len said, "We are thrilled with this most recent milestone and our ongoing partnership with AEMPS. This is another big step forward supported by our industry leading quality and operations teams. We anticipate this authorization will have an immediate impact in our ability to support our client's varied clinical programs and ensures long-term benefits to their future commercial supply."

About LSNE

LSNE is a privately held company with six GMP facilities four located in New Hampshire, one in Wisconsin and one located in Len, Spain. LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology, and medical device industries since 1997, specializing in a wide range of services including process cycle development, fill-finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), and analytical testing. Through the thoughtful integration of six processing facilities, qualified staffing, and extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a global market.

Media Contact

Jeff ClementVice President of Business Development(603) 668-5763info@lyophilization.comwww.lyophilization.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/lsne-leon-receives-approval-from-aemps-to-manufacture-biotechnology-based-therapeutic-products-301119798.html

SOURCE LSNE Contract Manufacturing

Link:
LSNE-Len Receives Approval From AEMPS To Manufacture Biotechnology Based Therapeutic Products - BioSpace

Albendazole Veterinary Drug Market Los Angeles, United State,, The global Albendazole Veterinary Drug market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Albendazole Veterinary Drug market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Albendazole Veterinary Drug market.

The research report is committed to giving its readers an unbiased point of view of the global Albendazole Veterinary Drug market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1702061/covid-19-impact-on-global-albendazole-veterinary-drug-market

The following Companies as the Key Players in the Global Albendazole Veterinary Drug Market Research Report:

, GSK, Sequent Scientific, Zoetis, AdvaCare Pharma, Guangdong Tianbao Biological Pharmaceutical Co., Ltd., Hanzhonghe Times Biotechnology Co., Ltd., Yahui Medicine, Beijing Shengmu Biotechnology Co., Ltd., Hebei Huabang Biological Technology Co., Ltd., Dongguan Meidehao Animal Pharmaceutical Co., Ltd., Sichuan Jinfeng Technology, Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd., Anhui Shenhui Agricultural Technology Co., Ltd., Foshan Zhengdian Biotechnology Co., Ltd., Shanghai Shenya, Tianjin Bijia Pharmaceutical Co., Ltd., Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province, Shimu Group, CSTP, Sneha Medicare Albendazole Veterinary Drug

Albendazole Veterinary Drug Market Product Type Segments

, Capsule Product, Table Product Albendazole Veterinary Drug

Albendazole Veterinary Drug Market Application Segments?<

Swine, Cattle, Others

Regions Covered in the Global Albendazole Veterinary Drug Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The scope of the Report:

The research report on the global Albendazole Veterinary Drug market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason, it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.The report also includes product portfolios and the list of products in the pipeline. It includes a thorough explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/1702061/covid-19-impact-on-global-albendazole-veterinary-drug-market

Strategic Points Covered in TOC:

1 Study Coverage 1.1 Albendazole Veterinary Drug Product Introduction 1.2 Market Segments 1.3 Key Albendazole Veterinary Drug Manufacturers Covered: Ranking by Revenue 1.4 Market by Type1.4.1 Global Albendazole Veterinary Drug Market Size Growth Rate by Type1.4.2 Capsule Product1.4.3 Table Product 1.5 Market by Application1.5.1 Global Albendazole Veterinary Drug Market Size Growth Rate by Application1.5.2 Swine1.5.3 Cattle1.5.4 Others 1.6 Coronavirus Disease 2019 (Covid-19): Albendazole Veterinary Drug Industry Impact1.6.1 How the Covid-19 is Affecting the Albendazole Veterinary Drug Industry

1.6.1.1 Albendazole Veterinary Drug Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Albendazole Veterinary Drug Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Albendazole Veterinary Drug Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Albendazole Veterinary Drug Market Size Estimates and Forecasts2.1.1 Global Albendazole Veterinary Drug Revenue 2015-20262.1.2 Global Albendazole Veterinary Drug Sales 2015-2026 2.2 Albendazole Veterinary Drug Market Size by Region: 2020 Versus 20262.2.1 Global Albendazole Veterinary Drug Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Albendazole Veterinary Drug Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Albendazole Veterinary Drug Competitor Landscape by Players 3.1 Albendazole Veterinary Drug Sales by Manufacturers3.1.1 Albendazole Veterinary Drug Sales by Manufacturers (2015-2020)3.1.2 Albendazole Veterinary Drug Sales Market Share by Manufacturers (2015-2020) 3.2 Albendazole Veterinary Drug Revenue by Manufacturers3.2.1 Albendazole Veterinary Drug Revenue by Manufacturers (2015-2020)3.2.2 Albendazole Veterinary Drug Revenue Share by Manufacturers (2015-2020)3.2.3 Global Albendazole Veterinary Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Albendazole Veterinary Drug Revenue in 20193.2.5 Global Albendazole Veterinary Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Albendazole Veterinary Drug Price by Manufacturers 3.4 Albendazole Veterinary Drug Manufacturing Base Distribution, Product Types3.4.1 Albendazole Veterinary Drug Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Albendazole Veterinary Drug Product Type3.4.3 Date of International Manufacturers Enter into Albendazole Veterinary Drug Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Albendazole Veterinary Drug Market Size by Type (2015-2020)4.1.1 Global Albendazole Veterinary Drug Sales by Type (2015-2020)4.1.2 Global Albendazole Veterinary Drug Revenue by Type (2015-2020)4.1.3 Albendazole Veterinary Drug Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Albendazole Veterinary Drug Market Size Forecast by Type (2021-2026)4.2.1 Global Albendazole Veterinary Drug Sales Forecast by Type (2021-2026)4.2.2 Global Albendazole Veterinary Drug Revenue Forecast by Type (2021-2026)4.2.3 Albendazole Veterinary Drug Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Albendazole Veterinary Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026) 5.1 Global Albendazole Veterinary Drug Market Size by Application (2015-2020)5.1.1 Global Albendazole Veterinary Drug Sales by Application (2015-2020)5.1.2 Global Albendazole Veterinary Drug Revenue by Application (2015-2020)5.1.3 Albendazole Veterinary Drug Price by Application (2015-2020) 5.2 Albendazole Veterinary Drug Market Size Forecast by Application (2021-2026)5.2.1 Global Albendazole Veterinary Drug Sales Forecast by Application (2021-2026)5.2.2 Global Albendazole Veterinary Drug Revenue Forecast by Application (2021-2026)5.2.3 Global Albendazole Veterinary Drug Price Forecast by Application (2021-2026) 6 North America 6.1 North America Albendazole Veterinary Drug by Country6.1.1 North America Albendazole Veterinary Drug Sales by Country6.1.2 North America Albendazole Veterinary Drug Revenue by Country6.1.3 U.S.6.1.4 Canada 6.2 North America Albendazole Veterinary Drug Market Facts & Figures by Type 6.3 North America Albendazole Veterinary Drug Market Facts & Figures by Application 7 Europe 7.1 Europe Albendazole Veterinary Drug by Country7.1.1 Europe Albendazole Veterinary Drug Sales by Country7.1.2 Europe Albendazole Veterinary Drug Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia 7.2 Europe Albendazole Veterinary Drug Market Facts & Figures by Type 7.3 Europe Albendazole Veterinary Drug Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Albendazole Veterinary Drug by Region8.1.1 Asia Pacific Albendazole Veterinary Drug Sales by Region8.1.2 Asia Pacific Albendazole Veterinary Drug Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam 8.2 Asia Pacific Albendazole Veterinary Drug Market Facts & Figures by Type 8.3 Asia Pacific Albendazole Veterinary Drug Market Facts & Figures by Application 9 Latin America 9.1 Latin America Albendazole Veterinary Drug by Country9.1.1 Latin America Albendazole Veterinary Drug Sales by Country9.1.2 Latin America Albendazole Veterinary Drug Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina 9.2 Central & South America Albendazole Veterinary Drug Market Facts & Figures by Type 9.3 Central & South America Albendazole Veterinary Drug Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Albendazole Veterinary Drug by Country10.1.1 Middle East and Africa Albendazole Veterinary Drug Sales by Country10.1.2 Middle East and Africa Albendazole Veterinary Drug Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE 10.2 Middle East and Africa Albendazole Veterinary Drug Market Facts & Figures by Type 10.3 Middle East and Africa Albendazole Veterinary Drug Market Facts & Figures by Application 11 Company Profiles 11.1 GSK11.1.1 GSK Corporation Information11.1.2 GSK Description, Business Overview and Total Revenue11.1.3 GSK Sales, Revenue and Gross Margin (2015-2020)11.1.4 GSK Albendazole Veterinary Drug Products Offered11.1.5 GSK Recent Development 11.2 Sequent Scientific11.2.1 Sequent Scientific Corporation Information11.2.2 Sequent Scientific Description, Business Overview and Total Revenue11.2.3 Sequent Scientific Sales, Revenue and Gross Margin (2015-2020)11.2.4 Sequent Scientific Albendazole Veterinary Drug Products Offered11.2.5 Sequent Scientific Recent Development 11.3 Zoetis11.3.1 Zoetis Corporation Information11.3.2 Zoetis Description, Business Overview and Total Revenue11.3.3 Zoetis Sales, Revenue and Gross Margin (2015-2020)11.3.4 Zoetis Albendazole Veterinary Drug Products Offered11.3.5 Zoetis Recent Development 11.4 AdvaCare Pharma11.4.1 AdvaCare Pharma Corporation Information11.4.2 AdvaCare Pharma Description, Business Overview and Total Revenue11.4.3 AdvaCare Pharma Sales, Revenue and Gross Margin (2015-2020)11.4.4 AdvaCare Pharma Albendazole Veterinary Drug Products Offered11.4.5 AdvaCare Pharma Recent Development 11.5 Guangdong Tianbao Biological Pharmaceutical Co., Ltd.11.5.1 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Corporation Information11.5.2 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.5.3 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.5.4 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Albendazole Veterinary Drug Products Offered11.5.5 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Recent Development 11.6 Hanzhonghe Times Biotechnology Co., Ltd.11.6.1 Hanzhonghe Times Biotechnology Co., Ltd. Corporation Information11.6.2 Hanzhonghe Times Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.6.3 Hanzhonghe Times Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.6.4 Hanzhonghe Times Biotechnology Co., Ltd. Albendazole Veterinary Drug Products Offered11.6.5 Hanzhonghe Times Biotechnology Co., Ltd. Recent Development 11.7 Yahui Medicine11.7.1 Yahui Medicine Corporation Information11.7.2 Yahui Medicine Description, Business Overview and Total Revenue11.7.3 Yahui Medicine Sales, Revenue and Gross Margin (2015-2020)11.7.4 Yahui Medicine Albendazole Veterinary Drug Products Offered11.7.5 Yahui Medicine Recent Development 11.8 Beijing Shengmu Biotechnology Co., Ltd.11.8.1 Beijing Shengmu Biotechnology Co., Ltd. Corporation Information11.8.2 Beijing Shengmu Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.8.3 Beijing Shengmu Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.8.4 Beijing Shengmu Biotechnology Co., Ltd. Albendazole Veterinary Drug Products Offered11.8.5 Beijing Shengmu Biotechnology Co., Ltd. Recent Development 11.9 Hebei Huabang Biological Technology Co., Ltd.11.9.1 Hebei Huabang Biological Technology Co., Ltd. Corporation Information11.9.2 Hebei Huabang Biological Technology Co., Ltd. Description, Business Overview and Total Revenue11.9.3 Hebei Huabang Biological Technology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.9.4 Hebei Huabang Biological Technology Co., Ltd. Albendazole Veterinary Drug Products Offered11.9.5 Hebei Huabang Biological Technology Co., Ltd. Recent Development 11.10 Dongguan Meidehao Animal Pharmaceutical Co., Ltd.11.10.1 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Corporation Information11.10.2 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.10.3 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.10.4 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Albendazole Veterinary Drug Products Offered11.10.5 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Recent Development 11.1 GSK11.1.1 GSK Corporation Information11.1.2 GSK Description, Business Overview and Total Revenue11.1.3 GSK Sales, Revenue and Gross Margin (2015-2020)11.1.4 GSK Albendazole Veterinary Drug Products Offered11.1.5 GSK Recent Development 11.12 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd.11.12.1 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Corporation Information11.12.2 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.12.3 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.12.4 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Products Offered11.12.5 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Recent Development 11.13 Anhui Shenhui Agricultural Technology Co., Ltd.11.13.1 Anhui Shenhui Agricultural Technology Co., Ltd. Corporation Information11.13.2 Anhui Shenhui Agricultural Technology Co., Ltd. Description, Business Overview and Total Revenue11.13.3 Anhui Shenhui Agricultural Technology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.13.4 Anhui Shenhui Agricultural Technology Co., Ltd. Products Offered11.13.5 Anhui Shenhui Agricultural Technology Co., Ltd. Recent Development 11.14 Foshan Zhengdian Biotechnology Co., Ltd.11.14.1 Foshan Zhengdian Biotechnology Co., Ltd. Corporation Information11.14.2 Foshan Zhengdian Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.14.3 Foshan Zhengdian Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.14.4 Foshan Zhengdian Biotechnology Co., Ltd. Products Offered11.14.5 Foshan Zhengdian Biotechnology Co., Ltd. Recent Development 11.15 Shanghai Shenya11.15.1 Shanghai Shenya Corporation Information11.15.2 Shanghai Shenya Description, Business Overview and Total Revenue11.15.3 Shanghai Shenya Sales, Revenue and Gross Margin (2015-2020)11.15.4 Shanghai Shenya Products Offered11.15.5 Shanghai Shenya Recent Development 11.16 Tianjin Bijia Pharmaceutical Co., Ltd.11.16.1 Tianjin Bijia Pharmaceutical Co., Ltd. Corporation Information11.16.2 Tianjin Bijia Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.16.3 Tianjin Bijia Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.16.4 Tianjin Bijia Pharmaceutical Co., Ltd. Products Offered11.16.5 Tianjin Bijia Pharmaceutical Co., Ltd. Recent Development 11.17 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province11.17.1 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Corporation Information11.17.2 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Description, Business Overview and Total Revenue11.17.3 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Sales, Revenue and Gross Margin (2015-2020)11.17.4 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Products Offered11.17.5 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Recent Development 11.18 Shimu Group11.18.1 Shimu Group Corporation Information11.18.2 Shimu Group Description, Business Overview and Total Revenue11.18.3 Shimu Group Sales, Revenue and Gross Margin (2015-2020)11.18.4 Shimu Group Products Offered11.18.5 Shimu Group Recent Development 11.19 CSTP11.19.1 CSTP Corporation Information11.19.2 CSTP Description, Business Overview and Total Revenue11.19.3 CSTP Sales, Revenue and Gross Margin (2015-2020)11.19.4 CSTP Products Offered11.19.5 CSTP Recent Development 11.20 Sneha Medicare11.20.1 Sneha Medicare Corporation Information11.20.2 Sneha Medicare Description, Business Overview and Total Revenue11.20.3 Sneha Medicare Sales, Revenue and Gross Margin (2015-2020)11.20.4 Sneha Medicare Products Offered11.20.5 Sneha Medicare Recent Development 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Albendazole Veterinary Drug Market Estimates and Projections by Region12.1.1 Global Albendazole Veterinary Drug Sales Forecast by Regions 2021-202612.1.2 Global Albendazole Veterinary Drug Revenue Forecast by Regions 2021-2026 12.2 North America Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.2.1 North America: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.2.2 North America: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.2.3 North America: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.3 Europe Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.3.1 Europe: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.3.2 Europe: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.3.3 Europe: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.4.2 Asia Pacific: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Albendazole Veterinary Drug Market Size Forecast by Region (2021-2026) 12.5 Latin America Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.5.1 Latin America: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.5.2 Latin America: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.5.3 Latin America: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porters Five Forces Analysis 13.5 Primary Interviews with Key Albendazole Veterinary Drug Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Albendazole Veterinary Drug Customers 14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.

Read more:
Global Albendazole Veterinary Drug Market: Trends, Opportunities, Restraints, Key Manufacturers And Forecast During The Projected Period 2020-2026...

This article was originally published here

Int J Stem Cells. 2020 Aug 31. doi: 10.15283/ijsc20076. Online ahead of print.

ABSTRACT

COVID-19 pandemic has brought the whole world stand still, locked down in their homes, infecting more than 8 million people, and many thousands (449,182) -have lost their lives across the globe. Due to lack of any definitive medicine or vaccine, treatment options are supportive of oxygenation, antiviral, antiretroviral drugs, antibiotics, fluid/ electrolyte, mechanical ventilation with ICU (Intensive Care Unit) support, and chloroquine/hydroxychloroquine have been tried to fight this infection. However, mortality due to severe pneumonia, ARDS (Acute Respiratory Distress Syndrome), and multiorgan failure arising from the overactive immune response (storm) mediated by cytokines remains a treatment challenge in elderly and patients with severe medical comorbidities. Recently, anti-inflammatory, angiogenic, immune-modular, and healing properties of intravenous injections of culture derived stem cells have been proposed and shown to benefits in a small number of patients with severe COVID-19 infections. Based on previous experience with other viral infections, convalescent plasma, and serum transfusion are being used as a source of neutralizing antibody/factors to minimize the effects of inflammatory cytokines in this infection. Immunotherapy with purified monoclonal antibodies and conditioned serum with a mixture of unique cytokines are also being developed. Regenerative Medicine has emerged as a crucial adjuvant tool in promoting healing and early recovery in severe COVID-19 infections and other supportive treatments.

PMID:32840231 | DOI:10.15283/ijsc20076

See the original post here:
Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections - DocWire News

This article was originally published here

Stem Cells Transl Med. 2020 Aug 27. doi: 10.1002/sctm.20-0245. Online ahead of print.

ABSTRACT

This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.

PMID:32856432 | DOI:10.1002/sctm.20-0245

Read more:
Regen med therapeutic opportunities for fighting COVID-19 - DocWire News

Reports Web presents the intelligent report title as Regenerative Medicine Market Covid-19 Impact Global Analysis and Forecasts by product, application and end user. Market is expected to provide several growth opportunities across the globe. The global market for asset performance management, on the basis of architecture, has been segmented into software and services.

Get Sample Copy of this Report at:

https://www.reportsweb.com/inquiry&RW00013543426/sample

Key Players:

Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporation and other predominate and niche players.

The target audience for the report on the market include, Manufactures, Market analysts, Senior executives, Business development managers, Technologists, R&D staff, Distributors, Investors, Governments, Equity research firms, Consultants.

The report provides complete details about the usage and adoption rate of regenerative medicine in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth.

The market report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global market based on type, and end user. It also provides market size and forecast till 2026 for overall Regenerative Medicine market globally.

Ask For Discount:

https://www.reportsweb.com/inquiry&RW00013543426/discount

Report Overview:

Section 1 Regenerative Medicine Product Definition

Section 2 Global Regenerative Medicine Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Regenerative Medicine Shipments

2.2 Global Manufacturer Regenerative Medicine Business Revenue

2.3 Global Regenerative Medicine Market Overview

2.4 COVID-19 Impact on Regenerative Medicine Industry

Section 3 Manufacturer Regenerative Medicine Business Introduction

Section 4 Global Regenerative Medicine Market Segmentation (Region Level)

Section 5 Global Regenerative Medicine Market Segmentation (Product Type Level)

Section 6 Global Regenerative Medicine Market Segmentation (Industry Level)

Section 7 Global Regenerative Medicine Market Segmentation (Channel Level)

Section 8 Regenerative Medicine Market Forecast 2020-2025

Section 9 Regenerative Medicine Segmentation Product Type

Section 10 Regenerative Medicine Segmentation Industry

Section 11 Regenerative Medicine Cost of Production Analysis

Section 12 Conclusion

Know more Exciting offers of Report:

https://www.reportsweb.com/buy&RW00013543426/buy/3500

*If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Contact Info:Name: Sameer JoshiEmail:[emailprotected]Company Name: ReportsWebWebsite: Reportsweb.com

Phone: +1-646-491-9876

About ReportsWeb:

ReportsWeb.com is a one stop shop of Market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

See the article here:
Regenerative Medicine Market | Leading industry players, products and services, Market Size and Trends 2020-2026 - The News Brok

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, announced that the company will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020 at 5:00 p.m. ET.

About ElevateBio

ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBios team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBios vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and transitional research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.

ElevateBios investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures HC.

ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, please visit http://www.elevate.bio.

Read more here:
ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference - Business Wire

The Global Video collaboration as a Service (VCaaS) Market was valued at USD 4 Billion in the year 2018. The market is expected to grow at a CAGR of 4.38% during 2019-2024, owing to increase in applications of video conferencing solutions among end users such as healthcare organizations, educational institutions and public sectors. Video conferencing has gained huge popularity and adoption among enterprises as a form of business communication.

Thevideo conferencing solutionshelp organizations to achieve desired goals by discussing the strategies and providing trainings over video conferences to enhance the business output. Introduction of web-based technology with fewer complications by the IT sector is further anticipated to propel the market significantly in near future. Further, surging investment towards innovative products, rising consumer demand, declining manufacturing cost, growing number of outlets and increasing research & development by leading service providers is also expected to augment the market growth.

The Final Report will cover the impact analysis of COVID-19 on this industry:

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10094853

A comprehensive research report published by Azoth Analytics in August 2019 aims to present the analysis of Global Video collaboration as a Service (VCaaS) Market. The report presents the analysis of Video collaboration as a Service (VCaaS) Market by Technology Type (Cloud Conferencing, On Premise Conferencing) and by Usage Type (Meetings, Webinars, Trainings). The Global Video collaboration as a Service (VCaaS) Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) and By Country (United States, Germany, China, India) for the historical period of 2017-2018 and the forecast period of 2019-2024.

Views Source Of Related Reports:

Video Collaboration As A Service (VCaaS) MarketCryptocurrency MarketCash Logistics MarketCar Rental MarketRegenerative Medicine Market Online Food Delivery And Takeaway MarketShea Butter MarketCT Scanner MarketVinyl Flooring MarketHigh Temperature Refractory Insulation Material MarketFloating Production System MarketCompounding Pharmacies MarketVascular Stent MarketRobotic Surgery MarketSalmon Market

Scope of the Report

Global Video Collaboration as a Service (VCaaS) Market (Actual Period: 2017-2018, Forecast Period: 2019-2024) Market Sizing, Growth, Forecast Analysis by Technology Type -Cloud Conferencing, On Premise Conferencing Analysis by Usage Type -Meetings, Webinars, Trainings Competitive Landscape Market Share Analysis

Regional Video Collaboration as a Service (VCaaS) Market North America, Europe, Asia Pacific, ROW (Actual Period: 2017-2018, Forecast Period: 2019-2024) Market Sizing, Growth, Forecast Analysis by Technology Type -Cloud Conferencing, On Premise Conferencing Analysis by Usage Type -Meetings, Webinars, Trainings

Country Analysis Video Collaboration as a Service (VCaaS) Market by Value United States, Germany, China, India (Actual Period: 2017-2018, Forecast Period: 2019-2024) Market Sizing, Growth, Forecast Analysis by Technology Type -Cloud Conferencing, On Premise Conferencing Analysis by Usage Type -Meetings, Webinars, Trainings

Other Report Highlights Strategic Recommendations Market Dynamics Trends, Drivers, Challenges Company Analysis Zoom Video Communications, Inc, Cisco WebEx, LogMein, Inc, BlueJeans Network, Intercall

Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research

Email:[emailprotected]

Phone: +1 313 462 0609

See the rest here:
Video Collaboration As A Service (VCaaS) Market Share, Trend, Opportunity, Affect On Demand By COVID-19 Pandemic And Forecast 2020-2024 - The Daily...

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19:https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers includeQGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

See the original post here:
How COVID-19 Pandemic Will Impact on 3D Cell Culture Market Growth and Demand in 2020 and Coming Future? - The Daily Chronicle

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have found a way, in mice and human tissue, to regenerate the cartilage that eases movement between bones.

Loss of this slippery and shock-absorbing tissue layer, called articular cartilage, is responsible for many cases of joint pain and arthritis, which afflicts more than 55 million Americans.

The researchers can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage before it is badly degraded.

Nearly 1 in 4 adult Americans suffer from arthritis, and far more are burdened by joint pain and inflammation generally.

The researchers figured out how to regrow articular cartilage by first causing slight injury to the joint tissue, then using chemical signals to steer the growth of skeletal stem cells as the injuries heal.

Cartilage has practically zero regenerative potential in adulthood, so once its injured or gone, what we can do for patients has been very limited, says co-senior author Charles K.F. Chan, assistant professor of surgery at Stanford Universitys School of Medicine.

Its extremely gratifying to find a way to help the body regrow this important tissue, Chan says.

The work builds on previous research that resulted in isolation of the skeletal stem cell, a self-renewing cell that is also responsible for the production of bone, cartilage and a special type of cell that helps blood cells develop in bone marrow.

Articular cartilage is a complex and specialized tissue that provides a slick and bouncy cushion between bones at the joints. When this cartilage is damaged by trauma, disease, or simply thins with age, bones can rub directly against each other, causing pain and inflammation, which can eventually result in arthritis.

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, says Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon and lead author Matthew Murphy, a visiting researcher at Stanford who is now at the University of Manchester.

I never felt anyone really understood how microfracture really worked, Murphy says. I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

For a long time, Chan says, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage?

The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan says. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says.

Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

One advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA, says co-senior author Michael Longaker, professor of surgery.

BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, he says. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain.

The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker says. You dont wait for damage to accumulateyou go in periodically and use this technique to boost your articular cartilage before you have a problem.

The work appears in the journal Nature Medicine.

Support for the research came from the National Institutes of Health, the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research, and the Arthritis National Research Foundation.

Source: Stanford University

Read the rest here:
Method regrows cartilage to cushion bones - Futurity: Research News

(PRESS RELEASE) PLEASANTON, CA IrisVision, the leader in digital vision technologies, today announced it has partnered with the Seva Foundation to develop new technology that will democratize vision healthcare around the world.

Seva Foundation is a global non-profit organization that provides eye care services to underserved communities across the globe. Since 1978, Seva has provided sight-saving surgeries, medicine and other eye care services to more than 40 million people globally.

In the first phase of this unique public-private partnership, Seva will provide IrisVision with a grant of $200,000 to help create new technologies to treat vision impairment, and even prevent blindness, in less privileged parts of our world. IrisVision, which is best known as the creator of an award-winning VR solution that restores sight for those with vision impairments and is currently developing new telehealth applications for its vision care platform, will contribute its extensive R&D talent, leadership and resources to the initiative.

This partnership with IrisVision will help Seva to continue delivering cutting-edge science and technology in eye health and vision care to the worlds underserved communities, said Seva Executive Director Kate Moynihan. One of our key tenets has been to continue investing in technology that advances eye care for affected and at-risk communities, wherever they may be. When we saw the ground-breaking work IrisVision is already doing in low vision aids, virtual vision diagnostics and remote delivery of eye care, we knew they have the scientific, technical and leadership talent to take our work even further.

According to IrisVision CEO and Co-founder Ammad Khan, Partnering with such a respected and prestigious organization as the Seva Foundation is an honor. They have established the pathways over their 40 years of hard work to restore sight to more than five million people in communities across the globe. In turn, our technology can help these communities regain the life-changing gift of sight. Together, we can truly make a difference in the world.

Here is the original post:
Seva Foundation Partners with IrisVision to Democratize Vision Care Through Innovation - InvisionMag

A new study shows vision loss is almost twice as common among military veterans than among civilians and was independently associated with self-reported illicit drug use.

The results should trigger increased awareness among both behavioral and eye health specialists, study author Justin Tyler McDaniel, PhD, associate professor of Public Health at Southern Illinois University's School of Human Sciences, Carbondale, told Medscape Medical News.

"As behavioral health folks routinely screen for alcohol misuse and drug use, they potentially could do some vision screening and refer folks to an optometrist if necessary," McDaniel said.

Conversely, ophthalmology professionals "perhaps could begin to implement screening for drug use during routine visits for eye checkup," and refer those who screen positive, he said.

The paper was published online August 13 in BMJ Military Health.

Studies have uncovered numerous associations between substance abuse and ocular injuries. For example, some have linked cocaine and methamphetamine with corneal injuries, and others have tied opiates, cocaine, methamphetamine and "bath salts," synthetic recreational stimulants, to iris injuries.

Justin Tyler McDaniel, PhD

Vision impairment has been associated with other health behaviors and conditions as well, the researchers note, including HIV, hypertension, smoking, diabetes, poor diet, physical activity, cancer, depression, gum disease, and socioeconomic status.

The new study aimed to more closely assess these streams of research "to see if there's any association between drug use and vision loss," said McDaniel.

The study included 1578 randomly selected participants (1472 civilians and 106 military service members or veterans) in the 2013 to 2018 cycles of the National Health and Nutrition Examination Survey (NHANES). NHANES is a nationally representative survey of health and nutrition status among US residents.

Since NHANES doesn't interview institutionalized individuals, which would include those in active military service, "we assume that all our sample was veterans," who were retired from active duty and living in the community, said McDaniel.

Survey questions determined use of cocaine, methamphetamine, and heroin, and of injection drug use. In addition to illicit drug use, study covariates included age, gender, race/ethnicity, education level, household income, blood pressure, diabetes, smoking, diet, sedentary time, health insurance, cancer history, depression, HIV status, and oral health.

The dependent variable was self-reported vision loss, which was obtained from the disability module in the NHANES. Respondents were asked if they are blind or have serious difficulty seeing even when wearing glasses.

The analysis showed that compared to civilians, veterans had a significantly higher prevalence of HIV-positive status (1.89% vs 0.41%; P = .038) and illicit drug use (20.75% vs 13.62%; P = .041).

While active military members tend to have lower rates of illicit drug use compared with civilians because of a "zero tolerance" policy and random drug testing, veterans retired from service may be dealing with posttraumatic stress disorder (PTSD) that "may be connected to beginning of illicit drug use," said McDaniel.

The rate of 1 in 5 veterans using illicit drugs seems high, but should be taken in context, said McDaniel, noting that the measure of illicit drug use in the survey is "quite broad."

"It could be someone who chronically uses illicit drugs or someone who just tried it one time," he noted.

More veterans in the study (8.49%) reported vision loss than civilians (4.48%). The higher prevalence of vision loss among veterans could be because of exposure to combat explosions, said McDaniel, but veterans also had more risk factors possibly linked to vision impairment.

For example, they had higher mean values of systolic blood pressure (125.8 vs 122.5 mm Hg), more pack years of cigarette smoking (8.29 vs 4.25), and more sedentary minutes per day (379.15 vs 337.07 min).

On the other hand, civilians had a higher prevalence of poor dietary habits; only 7.61% reported trying the MyPlate diet plan, which highlights elements of a healthy diet, vs 13.21% of veterans (P = .032).

In a model that adjusted for risk factors of vision loss including physical inactivity, diabetes, socioeconomic factors, and other health behaviors and conditions military service status (adjusted coefficient [aB] 0.91; P = .04) and illicit drug use (aB 0.72; P = .02) were associated with increased risk for vision loss. The next strongest predictor was HIV-positive status.

McDaniel stressed that the study shows only an association between drug use and vision loss, without determining from which direction the association is occurring.

"We have no way of inferring causation here," he said. "It could be that vision loss is a stressor that results in drug use, or it could be that a history of drug use leads to vision loss down the road."

McDaniel would like future research projects to determine where in the US veterans are most prone to illicit drug use and to vision loss. "Then we can begin to really refine and target some public health programming in those areas," he said.

"We could then maybe look at screening and brief interventions for service members who use drugs. And for vision loss, we could implement some sort of screening and vision rehabilitation programs."

Commenting on the study for Medscape Medical News, Kate Hendricks Thomas, PhD, from George Mason University's Department of Global and Community Health, Fairfax, Virginia, said the current study is a continuation of McDaniel's "interesting research" on the links between service experiences, behavioral health trends, and health outcomes among active military and veterans.

"The results of the present study are interesting in that they outline key predictor variables' influence on eye health," said Thomas.

"The study does a nice job of demonstrating empirically what we know about risk behaviors in military veterans," that they can lead to poorer health outcomes, said Thomas.

While substance abuse isn't the only behavior that can be correlated to poor eyesight, "in the present study, it demonstrated a strong enough link that screening veterans for addictive behaviors is warranted in the clinical setting."

The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors. McDaniel and Thomas have disclosed no relevant financial relationships.

BMJ Mil Health. Published online August 13, 2020. Abstract

For more Medscape Psychiatry news, join us on Twitter and Facebook

Go here to see the original:
Illicit Drug Use Tied to Vision Loss - Medscape

Sunu Band on wrist

Foresight is wonderful in business but when robotics engineer Marco Trujillo and legally blind chemist and serial entrepreneur Dr. Fernando Albertorio launched the Sunu Band in 2018, they couldnt possibly have imagined the new normal lurking just around the corner.

The Sunu Band is an advanced mobility aid for the blind and severely sight impaired.

Worn like a watch or wristband, the device uses sonar and echolocation to detect objects in the wearers path and then provides haptic vibrations to supply information on proximity. The closer the object, the more frequent the vibrations, which then fade when the object is further away.

During the coronavirus pandemic, maintaining social distancing has been a major challenge for those with severe vision impairments, leaving many fearful of leaving their homes.

In the event that an emergency global hackathon for medical engineers was organized to identify a technological solution to this complex challenge, the device to emerge might well closely resemble the Sunu Band.

Via a paired mobile app, Sunu even allows the user to select the distance at which they wish to be alerted, which ranges from 1.5 to 5 meters.

The band has been likened to a radar or flashlight for those with sight loss, identifying objects when the sensor is angled in their direction. It may also be understood as a form of sense enhancing augmented reality with a tactile overlay, rather than the visual one commonly seen in mainstream AR devices.

As the pandemic wore on, the company began to receive an increasing number of reports from its customers about how helpful the band is for maintaining social distancing.

Social distancing is the use case that all our customers have been telling us about, says Albertorio.

They find it particularly helpful for standing in a queue and being alerted when the person in front is starting to move forward, as well as the avoidance of people and obstacles in the supermarket.

Resembling a Fitbit, the Sunu Band also features a lightweight, cosmetically acceptable form factor, a design challenge that appears to have perpetually dogged manufacturers of low vision wearables.

Sunu Band on Wrist

The device also offers safety benefits by allowing users to operate their smartphone directly through the band, while the phone itself is tucked away snugly.

Sunu Band began life in Guadalajara, Mexico in 2013 after Trujillo undertook a community project at a school for the blind. During this time, he developed a keen interest in the way in which blind children learn to navigate and noted the upper body injuries they often sustain bumping into obstacles.

Trullijos path was to cross with Albertorio a year later when Albertorio was a mentor at the 2014 MassChallenge, a Boston-based global accelerator and competition for innovative start-ups.

The Sunu Band went on to win a Gold Award there and also won the Perkins School for the Blind Technology Sidecar Prize, later winning a Global Elevate Award in 2016.

Prior to its market launch in 2018, Sunu also went through Y Combinator, a highly competitive Silicon Valley-based accelerator program.

Albertorio joined up with the fledgling company, not just as a serial tech entrepreneur but in his capacity as a legally blind individual.

He has albinism, which, in his case, results in severe light sensitivity and eye movement disorders.

The band is not envisaged as a replacement for a white cane or a guide dog but as an additional novel layer of sense enhancement.

The original use case considered was the avoidance of raised or overhead obstacles, anything not being picked up by a regular sweep of the cane.

Chris McNally, a low vision technology enthusiast, who was born with a form of Retinitis pigmentosa that severely impairs his ability to see in low light, is a dedicated user of the device and offers up some fascinating insights on how the band has remapped his senses.

When navigating, it feels like my brain has been so starved of information that when something new and useful is incorporated, it latches right on to it, he says.

Feedback from the band is now integrated so deeply into the way I move around; Im not even consciously thinking about the new input coming in anymore.

As I sweep back and forth, he continues, Im sensing walls and doorways. If I feel it pulsing faster, I know its a person coming at me, which is awesome, particularly because of the situation with Covid.

This sense enhancing aspect is something which Katrina Best, an Orientation and Mobility Specialist based in Collier County, Florida working with school children and adults living with sight loss has also noted.

I was working with a client in his fifties who is now totally blind and I wanted to try out the Sunu Band with him, she says.

We walked to a restaurant and I put it on him and he chuckled because he could suddenly tell when the waitress was walking past and ignoring us. The wearer can really feel when people are walking around them.

I feel like its a tool for independence, she continues. Too often, students I see in grade schools and older adults tend to just rely on others.

In terms of a future pipeline, the interoperability of the hardware with a dedicated smartphone app means the opportunities to expand functionality are limitless.

This may include more granular mapping and guidance for blind people, even down to a street furniture level, and as a platform technology, further integration with third-party apps, such as Be My Eyes or even Uber.

As a company, we want to challenge certain societal perceptions where people with disabilities are viewed as helpless, says Albertorio.

We believe wearable technologies that can augment human abilities have a big role to play in creating equity for disabled people through bridging the information gap and empowering and enhancing the senses.

Over the socially distanced shorter term, the company is exploring other use cases for the Sunu Band. This could include individuals with suppressed immune systems seeking an extra level of protection when out and about.

There may also be mainstream applications for employees wishing to monitor distancing in closed or crowded working environments, such as in the hospitality sector, or for certain leisure activities where vision is reduced, like caving.

The Sunu Band may not quite yet feature all the bells and whistles of the Apple Watch but priced at $299 (three quarters of the price of the tech giants device), it offers those who could benefit so much more.

After all, innovative assistive technology devices are more than just cool gadgets to enjoy. They hack the human operating system at a fundamental level and can, thereby, promote unique and personalized modalities for independence.

Excerpt from:
Sunu Band The Smart Wearable Helping Blind People Maintain Social Distance - Forbes

Report is a detailed study of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is to help making reliable strategic decisions regarding the opportunities in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. It offers business accounts, industry investors, and industry segments with consequential insights enhancing decision making ability.[emailprotected] or call us on +1-312-376-8303.

Request Report from CMR Website:https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report

Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segmentation by Type: Platelet Rich Plasma Injections, Stem Cell Therapy

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segmentation by Applications: Dermatology Clinics, Hospitals

Major Market Players with an in-depth analysis: Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute

Request Free Sample Copy of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research [emailprotected] https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#download_report

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report offers the current state of the market around the world. The report starts with the market outline and key components of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies business and market elements.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report 2020 (Coronavirus Impact Analysis on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies product has been completely profiled along with their SWOT. Some of the key players include Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

DOWNLOAD FREE SAMPLE [emailprotected]: https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#download_report

Chapters Define in TOC (Table of Content) of the Report:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, SegmentationOverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: Complete profiling and analysis of ManufacturersChapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expensesChapter 10: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 11: Marketing Strategy Analysis, Distributors/TradersChapter 12: Market Effect Factors AnalysisChapter 13: Market ForecastChapter 14: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Research Findings and Conclusion, Appendix, methodology and data source To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#table_of_contents

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2027.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients.

Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report

Go here to read the rest:
Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research Study 2020 Insights with COVID-19 Impact Analysis by 2020Orange...

MarketsandResearch.biz has published the latest market research study on Global Cell Isolation Technology Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which investigates a few critical features of the market such as industry condition, division examination, market insights. The report studies the global Cell Isolation Technology market share, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels. The report has referenced down to earth ideas of the market in a straightforward and unassuming way in this report. The research contains the categorization of the market by top players/brands, region, type, and end-user. The report exhaustive essential investigation of current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The research report has comprehensively included numbers and figures with the help of graphical and pictorial representation which embodies more clarity on the global Cell Isolation Technology market. Then the report delivers key information about market players such as company overview, total revenue (financials), market potential, global presence, as well as market share, prices, production sites and facilities, products offered, and strategies adopted by them. Market status and outlook of global and major regions, from angles of players, countries, product types, and end industries have been analyzed.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/82010

Key strategic manufacturers included in this report: Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Merck, Stemcell Technologies, BD Biosciences, GE Healthcare, Terumo BCT

Market Potential:

Key market vendors have been predicted to obtain the latest opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Also, many of the market contenders are forecasted to make a foray into the emerging economies to find new opportunities. The global Cell Isolation Technology market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in this market.

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of in these countries from 2015 to 2020, which covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

The market can be segmented into product types as: Centrifugation, Flow Cytometry, Cell Electrophoresis

The market can be segmented into applications as: Stem cell research, Cancer research, Tissue regeneration, In-vitro diagnostics, Others

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/82010/global-cell-isolation-technology-market-2020-by-company-regions-type-and-application-forecast-to-2025

Reasons for Buying Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Visit link:
Global Cell Isolation Technology Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - Scientect

In 2029, the Suramin Sodium market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Suramin Sodium market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Suramin Sodium market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Suramin Sodium market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2769976&source=atm

Global Suramin Sodium market report on the basis of market players

The report examines each Suramin Sodium market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Suramin Sodium market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Segment by Type, the Suramin Sodium market is segmented intoTabletCapsule

Segment by Application, the Suramin Sodium market is segmented intoAntitumor DrugAntiviral DrugsImmunomodulator

Regional and Country-level AnalysisThe Suramin Sodium market is analysed and market size information is provided by regions (countries).The key regions covered in the Suramin Sodium market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Suramin Sodium Market Share AnalysisSuramin Sodium market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Suramin Sodium business, the date to enter into the Suramin Sodium market, Suramin Sodium product introduction, recent developments, etc.

The major vendors covered:MP BiomedicalsBOC ScienceVWRSigma-AldrichCayman ChemicalStemcell Technologies

Report available at a discounted price exclusively!!! Offer ends today!!!

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2769976&source=atm

The Suramin Sodium market report answers the following queries:

The Suramin Sodium market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2769976&licType=S&source=atm

Research Methodology of Suramin Sodium Market Report

The global Suramin Sodium market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Suramin Sodium market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Suramin Sodium market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

See the article here:
Suramin Sodium Market Projected to Witness a Single-Digit CAGR During 2019-2025 - StartupNG